top of page


Dive into the Biopharma Space

Stay up-to-date on major biopharma news, deeper dives into specific companies and biopharma themes, and how it all relates to biopharma partners.

Cell & Gene Tx Companies in BioCapital Region

The BioCapital region is a hub for biotechnology innovation, with significant growth in the past few decades. Within the groundbreaking field of cell therapy, we see an impressive 28 cell & gene therapy companies headquartered in the region, each with at least an active cell and/or gene therapy program in our BiopharmIQ database. Maryland boasts the highest concentration of cell therapy company headquarters (FIG. 1 📷).

FIG. 1. BioCapital Biopharma Companies.


Representative Company Snapshots

Sirnaomics (HKG: 2257)

Status: Public

Location: Gaithersburg, MD

Technologies: RNA-based therapeutics

Overview: Sirnaomics is developing RNA-based therapeutics for Cancer, Hematologic, infectious diseases, and others. STP705 is their lead drug candidate, a dual TGF-ß1 & COX-2 inhibitor which are well-validated gatekeeper targets for oncology and fibrosis disease drug development.

Cartesian Therapeutics (NASDAQ: RNAC)

Status: Public

Location: Gaithersburg, MD

Technologies: mRNA cell therapeutics

Overview: a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a potential first-in-class mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis.

Virion Therapeutics

Status: Private

Location: Newark, DE

Technologies: T-cell immunotherapeutics

Overview: a clinical-stage company developing novel T cell-based immunotherapies for cancer and chronic infectious diseases. VRON-0200 is the company's most advanced therapeutic candidate which treats chronic HBV infection and is currently in Ph1 clinical trials.

Are you a CRO, CMO, or Biopharma vendor? Get a list of 100's of biopharma companies with cell therapy products. Perfect for sales and business development activities. Access our free report here:

Article History

Original published: 03/13/24 RF

This article is not investment or legal advice.


bottom of page